Clinical Trial Update: A Study to Assess the Adverse Events, Change in Disease Activity, and How Oral ABBV-711 Tablets Move Through the Body as a Monotherapy and in Combination With Intravenously Infused Budigalimab (ABBV-181), in Adults With Advanced Squamous Tumors [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating oral ABBV-711 as a monotherapy and in combination with intravenous Budigalimab (ABBV-181) in adults with advanced squamous tumors, focu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Squamous Cell Carcinoma

Drugs mentioned

• ABBV-711
• budigalimab (budigalimab)

Snippet

Sponsor: AbbVie | Conditions: Advanced Squamous Tumors | Phase 1 | Status: RECRUITING